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Abstract
Background: There are some data showing that repurposed drugs used for the 
Coronavirus disease- 19 (COVID- 19) have potential to increase the risk of QTc pro-
longation and torsade de pointes (TdP), and these arrhythmic side effects have not 
been adequately addressed in COVID- 19 patients treated with these repurposed 
medications.
Methods: This is the prospective study of 2403 patients hospitalised at 13 hospi-
tals within the COVID- 19 epicentres of the Iran. These patients were treated with 
2 of 11  |     HAGHJOO et Al.
1  | INTRODUC TION
As the coronavirus disease 2019 (COVID- 19) global pandemic 
spreads across the world, the use of off- label repurposed drugs, 
such as chloroquine/hydroxychloroquine with and without azithro-
mycin, have gained attraction, appearing in international and do-
mestic therapeutic guidelines. The presumed efficacies of these 
drugs mainly originated from in vitro investigations1- 3 and small 
non- randomised studies.4,5 However, subsequent randomised 
studies have failed to confirm these findings.6- 9 Simultaneously, a 
group of antiviral agents including lopinavir/ritonavir, atazanavir/
ritonavir, oseltamivir, favipiravir and remdesivir have been tested 
in prospective observational and randomised clinical trials in dif-
ferent countries.10- 12
Although these repurposed drugs are generally well- tolerated 
in clinical practice, some of these drugs such as chloroquine, hy-
droxychloroquine, azithromycin and lopinavir/ritonavir have been 
clearly shown to increase the risk of QT interval prolongation and 
torsade de pointes (TdP).13 There are no adequate clinical data on 
QT prolonging effect and torsadogenic potentials of other drugs 
such as atazanavir/ritonavir, oseltamivir, favipiravir and remde-
sivir. This risk of arrhythmic death could be further amplified if 
multiple medications are used in combination. Although there are 
some studies evaluating QT prolongation and TdP risk in those 
treated with chloroquine, hydroxychloroquine with and without 
azithromycin in COVID- 19 patients,14- 16 the present study evalu-
ated eight repurposed drugs in a large of number of the patients 
with COVID- 19.
chloroquine, hydroxychloroquine, lopinavir/ritonavir, atazanavir/ritonavir, oseltami-
vir, favipiravir and remdesivir alone or in combination with azithromycin. The primary 
outcome of the study was incidence of critical QTc prolongation, and secondary out-
comes were incidences of TdP and death.
Results: Of the 2403 patients, 2365 met inclusion criteria. The primary outcome of 
QTc	≥	500	ms	and	∆QTc	≥	60	ms	was	observed	in	11.2%	and	17.6%	of	the	patients,	
respectively.	The	secondary	outcomes	of	TdP	and	death	were	reported	in	0.38%	and	
9.8%	of	the	patients,	 respectively.	The	risk	of	critical	QT	prolongation	 increased	 in	
the presence of female gender, history of heart failure, treatment with hydroxychlo-
roquine, azithromycin combination therapy, simultaneous furosemide or beta- blocker 
therapy and acute renal or hepatic dysfunction. However, the risk of TdP was pre-
dicted by treatment with lopinavir- ritonavir, simultaneous amiodarone or furosemide 
administration and hypokalaemia during treatment.
Conclusion: This cohort showed significant QTc prolongation with all COVID- 19 med-
ications studied, however, life- threatening arrhythmia of TdP occurred rarely. Among 
the repurposed drugs studied, hydroxychloroquine or lopinavir- ritonavir alone or in 
combination with azithromycin clearly demonstrated to increase the risk of critical QT 
prolongation and/or TdP.
What’s known
• Hydroxychloroquine/chloroquine alone or in combination with azithromycin clearly demon-
strated to increase the risk of critical QT prolongation or induction of Torsades de Pointes 
(TdP).
What’s new
• This study clearly showed that other COVID- 19 repurposed medications including lopinavir/
ritonavir, atazanavir/ritonavir, oseltamivir, favipiravir, and remdesivir alone or in combination 
with azithromycin have potential to increase the risk of significant QTc prolongation.
• Although all the studied COVID- 19 medications has potential for the significant QT prolon-
gation, life- threatening arrhythmia of TdP occurred rarely.
• Among the repurposed drugs studied, hydroxychloroquine or lopinavir- ritonavir alone or in 
combination with azithromycin clearly demonstrated to increase the risk of critical QT pro-
longation or induction of TdP.
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Our country is seriously involved with the covid- 19 outbreak 
and many patients received these drugs or are going to receive in 
the future. Therefore, we designed this study to evaluate the risk 
of QT interval prolongation, TdP and death among the hospitalised 
COVID- 19 patients treated with chloroquine, hydroxychloroquine, 
lopinavir/ritonavir, atazanavir/ritonavir, oseltamivir, favipiravir and 
remdesivir alone or in combination with azithromycin.
2  | METHODS
2.1 | Study population
In this multicentre national survey, we prospectively collected data 
on pharmacotherapy of patients with COVID- 19. Between June 
2020 and October 2020, a total of consecutive 2403 patients were 
enrolled from 13 hospitals within the COVID- 19 epicentres of the 
Iran. For the purpose of this study, we included all patients who 
are 18 years of age and older, have positive polymerase chain reac-
tion (PCR) for SARS- CoV- 2 in nasopharyngeal swab and/or typical 
chest- CT findings and treated with chloroquine, hydroxychloro-
quine, lopinavir/ritonavir, atazanavir/ritonavir, tocilizumab, oseltami-
vir, favipiravir and remdesivir as monotherapy or in combination 
with azithromycin. In addition, patients should have an interpret-
able baseline ECG and at least one ECG recorded on second day of 
therapy or later. Baseline ECGs otherwise unsuitable for accurate 
QT interval measurement were excluded. Patients without 12- lead 
ECG or rhythm strip recordings on day 2 of drug therapy or later 
were also excluded. This study was approved by the Research Ethics 
Committee of National Institute for Medical Research Development 
(Approval ID: IR.NIMAD.REC.1399.055) and all patients gave written 
informed consent for participation in the study.
2.2 | Data collection
Data were collected by patient interview and review of medical 
records. Collected data were entered into web- based electronic 
database (Regitory, Tehran, Iran: https://regit ory5.rhc.ac.ir). All 
information was kept confidential and password protected. We 
gathered all data related to patient demographics, associated comor-
bidities (ie heart disease, heart failure, renal failure, liver disease), 
laboratory data (ie electrolyte levels, renal function test and liver 
function tests), drug history (including COVID- 19 drugs and other 
QT prolonging drugs), electrocardiographic findings at baseline ECG 
and after drug intake, and all important events during admission or 
follow- up (TdP, sudden death and mortality).
2.3 | Drug therapy protocols
The decision to treat with above- mentioned drugs was based on the 
clinical decision of the treating physician and national guidelines. 
The treatment regimens were as follows: (1) Chloroquine 500 mg by 
mouth twice daily for 1 day followed by 250 mg by mouth twice 
daily for 5- 7 days; (2) Hydroxychloroquine 400 mg by mouth twice 
daily for 1 day followed by 200 mg by mouth twice daily for 5- 7 days; 
(3) Azithromycin 500 mg by mouth daily for 1 day and followed by 
250 mg daily for 5 days; (4) Lopinavir/ritonavir 200/50 mg twice daily 
for 5 days; (5) Atazanavir/ritonavir 300/100 mg daily for 5 days; (6) 
Oseltamivir 75 mg twice daily for 5 days; (7) Favipiravir 1600 mg 
twice daily for 1 day and then 600- 800 mg twice daily for 5 days; 
(8) Remdesivir 200 mg daily for first day and then 100 mg daily for 
5- 7 days.
All decisions on patient care were taken by the hospital clinicians, 
and no attempt was made by research team to influence their deci-
sions. Furthermore, decisions regarding situations such as critical QT 
prolongation and or TdP were at the sole discretion of the physicians 
responsible for patient care.
2.4 | QT measurements
A baseline QTc was measured from a 12- lead ECG before treatment. 
If no baseline ECGs were available, ECGs recorded within 30 days of 
drug initiation were used for the baseline measures. On- treatment 
QT measurements were done using 12- lead ECGs or single- lead 
rhythm strip of lead II.
QT measurements were independently reviewed and validated 
by 13 expert cardiologists who were blinded to other patient data. 
The QT intervals were calculated manually from either lead II or V5 
using the tangent method17 and QT corrections were done using 
Bazett's formula. For patients with intraventricular conduction de-
lays (paced rhythms or bundle branch block), a modified QTc was 
calculated using the formula: modified QTc =	(QT-	(QRS-	120))/√RR.18 
Using ECGs recorded before and during treatment, we also assessed 
the	change	from	baseline	in	QTc	(∆QTc).
2.5 | Study outcomes
The primary outcome of the study was incidence of critical QTc 
prolongation,	 defined	 as	maximum	on-	therapy	QTc	 ≥	 500	ms	 (if	
QRS <	120	ms)	or	QTc	≥	550	ms	 (if	QRS	≥	120	ms)	and	∆QTc	of	
≥60	ms	Secondary	outcomes	were	incidences	of	documented	TdP	
and all- cause mortality. Cause of death was adjudicated by review 
of the resuscitation records from all patients with attempted re-
suscitation, and the reviewers of these data were blinded to the 
QTc data. TdP should be clearly documented by a single- lead ECG 
tracing.
2.6 | Statistical analysis
Fitness of interval variables with normal distribution was assessed 
by one- sample Kolmogorov- Smirnov test. Data are presented as 
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mean ± SD for continuous and frequency (percentage) for cate-
gorical variables. Comparisons of characteristics were made using 
Pearson's chi- square or Fisher's exact test for categorical variables 
and unpaired Student t test for continuous variables. The ECG char-
acteristics before versus during drug therapy were compared using 
paired t test. Independent predictors for prolonged QTc were iden-
tified by logistic regression models. P value < .05 was considered 
as statistically significant. Statistical analyses were performed using 
IBM SPSS Statistics 22 for Windows (IBM Corp, Armonk, NY).
3  | RESULTS
3.1 | Patient characteristics
Clinical characteristics of the study population were presented in 
Table 1. Of the 2403 patients initially enrolled in the study, 2365 met 
inclusion criteria and 38 were excluded because of non- interpretable 
baseline ECG or incomplete clinical data. Of 2365 patients, 1311 
(54.6%)	were	men	and	the	mean	age	was	59.6	± 16.4 years (range, 
18- 99 years). The most common comorbidities were hypertension 
(35.8%),	diabetes	mellitus	 (31%),	non-	ischemic	structural	heart	dis-
ease	(14.9%)	and	coronary	artery	disease	(12.9%).




roquine group. Lopinavir/ritonavir and atazanavir/ritonavir were ad-
ministered	to	689	(29%)	and	16	(0.7%)	of	the	patients,	respectively.	
Azithromycin	was	added	to	206	 (30%)	patients	 in	 lopinavir/ritona-
vir	 group	 and	 4	 (25%)	 in	 atazanavir/ritonavir	 group.	One-	hundred	
twenty-	one	 patients	 (5%)	were	 treated	with	 oseltamivir,	 including	
103 monotherapy and 18 combination therapy with azithromycin. 
Other antiviral agents favipiravir and remdesivir were also employed 
in	33	(1.4%)	and	67	(2.8%)	patients,	respectively.
3.2 | Electrocardiographic characteristics
A 12- lead ECG was obtained from all patients before treatment. ECG 
characteristics were summarised in Table 2. The mean baseline QTc 
interval was 399.5 ±	42.5	ms	and	48	patients	(2.0%)	had	a	baseline	
QTc	≥	500	ms	On-	treatment	measurements	showed	significant	 in-
crease in QTc interval (432.5 ± 53.8 ms, P < .001). All COVID- 19 
drug regimens were associated with significant increase in on- 
treatment QTc (all P < .05). Maximal increases in on- treatment QTc 
were observed following combination of azithromycin with either 
chloroquine, lopinavir/ritonavir or hydroxychloroquine (Table 3). 
Compared with monotherapy, combination therapy led to signifi-
cantly	more	increase	in	on-	treatment	QTc	(∆QTc:	26.4	ms	vs	37.6	ms,	
P <	.001)	and	higher	number	of	the	patients	with	QTc	≥	500	ms	(8.0%	
vs	13.5%,	P <	.001)	and	∆QTc	≥	60	ms	(12%	vs	212.6%,	P < .001).
3.3 | Outcome analysis
Primary and secondary outcome for different drug regimens were 
summarised in Table 4. After receiving COVDI- 19 medications, 
QTc	≥	500	ms	and	∆QTc	≥	60	ms	were	detected	in	11.2%	(n	= 266) 
and	17.6%	(n	= 417) of the patients respectively.
Compared with those with QTc < 500 ms, the patients with 
QTc	≥	500	ms	were	more	likely	to	have	history	of	heart	failure	and	
chronic kidney disease (CKD), more likely to receive hydroxychlo-
roquine, lopinavir- ritonavir, azithromycin, diuretics, beta- blockers 
and calcium antagonists and more likely to develop acute renal or 
hepatic dysfunction during treatment. However, female gender, 
TA B L E  1   Baseline clinical characteristics
Characteristic (n = 2365) Value
Age (y) 59.6 ± 16.4
Male gender 1303 (54.6)
Nasopharyngeal PCR test 2059 (86)
Positive PCR result 1586 (77)
Lung CT scan 778 (33)
COVID- 19 pneumonia in lung CT scan 766 (98.5)
Coronary artery disease 308 (13)
Non- ischemic structural heart disease 355 (15)
Heart failure 186 (7.8)
Chronic kidney disease 174 (7.3)
Chronic hepatic disease 16 (0.7)
Hypertension 855 (35.8)
Diabetes 742 (31)
Creatinine level (mg/dL) 1.4 ± 1.0
Potassium level (mEq/L) 4.3 ± 2.0
Magnesium level (mEq/L) 2.1 ± 0.74
Aspartate Aminotransferase level (µ/L) 52 ± 90
Alanine Aminotransferase level (µ/L) 41 ± 55
Bilirubin level 1.3 ± 1.4
Note: Continuous variables were presented as mean ± SD. Categorical 
variables	are	presented	as	n	(%).
Abbreviations: COVID- 19, coronavirus disease 2019; CT, computed 
tomography; PCR, polymerase chain reaction.






Heart rate (bpm) 90.5 ± 28.0 90.2 ± 20.0 .51
PR interval (ms) 163.0 ± 33.0 163.0 ± 39.0 <.001
QRS width (ms) 84.5 ± 22.0 86.5 ± 25.0 <.001
QT interval (ms) 340.5 ± 41.7 356.3 ± 52.4 <.001
QTc interval (ms) 399.5 ± 42.5 432.5 ± 54.0 <.001
Note: Variables were presented as mean ± SD.
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history of heart failure, acute hepatic dysfunction, treatment with 
hydroxychloroquine, azithromycin combination therapy and simul-
taneous furosemide therapy remained as independent predictors of 
QTc	≥	500	ms	in	multivariate	analysis	(Table	5).
In	comparison	with	those	who	had	∆QTc	< 60 ms, patients with 
∆QTc	≥	60	ms	were	more	likely	to	have	history	of	CKD,	more	likely	
to develop acute renal or hepatic dysfunction during treatment, 
and more likely to receive hydroxychloroquine, lopinavir- ritonavir, 
oseltamivir, azithromycin combination therapy, furosemide and 
beta- blockers. In multivariate analysis, simultaneous beta- blocker 
therapy and acute renal failure remained as independent predictors 
for	∆QTc	≥	60	ms	(Table	6).
TA B L E  3   QT change with different COVID- 19 pharmacotherapy
COVID drug Baseline QTc On- treatment QTc ∆QTc P value
Chloroquine (n = 9) 389.8 ± 33.0 447.6 ± 35.0 +57.8 .002
Chloroquine monotherapy (n = 6) 394.0 ± 32.0 432.0 ± 31.0 +38 .002
Chloroquine + Azithromycin (n = 3) 381.6 ± 40.0 479.3 ± 17.0 +97.7 .002
Hydroxychloroquine (n = 1430) 399.0 ± 45.0 436.0 ± 57.0 +37 <.001
Hydroxychloroquine monotherapy (n = 350) 394.4 ± 44.0 428.4 ± 59.0 +34 <.001
Hydroxychloroquine + Azithromycin (n = 1080) 400.5 ± 45.0 438.9 ± 56.5 +38.4 <.001
Lopinavir/ritonavir (n = 689) 395.5 ± 38.5 422.5 ± 49.0 +27 <.001
Lopinavir/ritonavir monotherapy (n = 483) 388 ± 36.8 409.3 ± 36.8 +21.3 <.001
Lopinavir/ritonavir + Azithromycin (n = 206) 413.9 ± 36.6 453.5 ± 39.3 +39.6 <.001
Atazanavir/ritonavir (n = 16) 427.0 ± 28.5 456.5 ± 32.3 +29.6 <.001
Atazanavir/ritonavir monotherapy (n = 12) 423.6 ± 29.7 453.5 ± 34.0 +30 <.001
Atazanavir/ritonavir + Azithromycin (n = 4) 437.2 ± 38.2 465.7 ± 28.6 +28.5 <.001
Oseltamivir (n = 121) 410.0 ± 38.3 435.0 ± 44.3 +25 <.001
Oseltamivir monotherapy (n = 18) 413.2 ± 35.9 432.7 ± 31.6 +19.5 <.001
Oseltamivir + Azithromycin (n = 103) 409.5 ± 38.8 435.6 ± 46.3 +26.1 <.001
Favipiravir (n = 33) 414.4 ± 22.9 433.5 ± 32.0 +19.0 <.001
Remdesivir (n = 67) 418.3 ± 32.0 442.7 ± 37.3 +24.4 <.001
Note: Continuous variables were presented as mean ±	SD.	Categorical	variables	are	presented	as	n	(%).
TA B L E  4   Primary and secondary outcomes with different drug regimens
COVID drug QTc ≥ 500 ms ∆QTc ≥ 60 ms TdP
Chloroquine (n = 9) 0 3 (33.0) 0
Chloroquine (n = 6) 0 2 (33.0) 0
Chloroquine + Azithromycin (n = 3) 0 1 (33.0) 0
Hydroxychloroquine (n = 1430) 196 (13.7) 300 (21.0) 4 (0.3)
Hydroxychloroquine monotherapy (n = 350) 41 (11.7) 63 (18.0) 0
Hydroxychloroquine + Azithromycin (n = 1080) 155 (14.4) 237 (22.0) 4 (0.4)
Lopinavir/ritonavir (n = 689) 52 (7.5) 90 (13.0) 5 (0.78)
Lopinavir/ritonavir (n = 483) 27 (5.6) 38 (8.0) 0
Lopinavir/ritonavir + Azithromycin (n = 206) 25 (12.0) 52 (25.0) 5 (2.4)
Atazanavir/ritonavir (n = 16) 3 (18.7) 2 (12.5) 0
Atazanavir/ritonavir (n = 12) 2 (16.7) 1 (8.3) 0
Atazanavir/ritonavir + Azithromycin (n = 4) 1 (25) 1 (25) 0
Oseltamivir (n = 121) 8 (6.6) 13 (10.7) 0
Oseltamivir (n = 18) 0 3 (16.7) 0
Oseltamivir + Azithromycin (n = 103) 8 (7.8) 10 (9.7) 0
Favipiravir (n = 33) 1 (3.0) 3 (9.0) 0
Remdesivir (n = 67) 6 (9.0) 6 (9.0) 0
Note: Variables	are	presented	as	n	(%).
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During	the	study	period,	a	total	of	9	patients	(0.38%)	experi-
enced TdP and required emergent defibrillation. Of the 9 patients 
who had TdP, 4 were treated with combination of hydroxychlo-
roquine and azithromycin and 5 with combination of lopinavir/ri-
tonavir and azithromycin. Patients who developed TdP were more 
likely to have history of non- ischemic structural heart disease, 
history of heart failure, history of CKD, history of chronic liver 
disease, more likely to receive lopinavir- ritonavir, azithromycin 
combination therapy, furosemide, metolazone, amiodarone and 
other	QT	prolonging	drugs,	more	likely	to	have	QTc	≥	500	ms	and	
∆QTc	≥	60	ms	during	treatment,	and	more	likely	to	develop	elec-
trolyte abnormalities (hypokalaemia, hypocalcaemia) and acute 
renal dysfunction. However, treatment with lopinavir- ritonavir, 
simultaneous amiodarone or furosemide administration and 
Risk factors
Univariate analysis Multivariate analysis
P value OR 95% CI P value OR 95% CI
Female gender .167 0.83 0.65- 1.08 .012 0.71 0.55- 0.93
Coronary artery 
disease
.096 1.35 0.95- 1.90
Heart failure <.001 2.90 2.00- 4.16 <.001 2.17 1.40- 3.30
Chronic kidney 
disease
.017 1.66 1.09- 2.50
Acute renal 
dysfunction
<.001 1.85 1.40- 2.40
Acute liver 
dysfunction
<.001 2.20 1.64- 2.97 <.001 1.96 1.43- 2.70
Hydroxychloroquine <.001 1.96 1.47- 2.60 <.001 1.78 1.29- 2.44
Lopinavir- ritonavir <.001 0.56 0.40- 0.77
Oseltamivir .098 0.54 0.26- 1.13
Azithromycin 
coadministration
<.001 1.80 1.37- 2.40 .023 1.40 1.05- 1.95
Furosemide <.001 2.70 1.97- 3.70 .004 1.70 1.19- 2.47
Hydrochlorothiazide .013 2.68 1.19- 6.03
Betablocker <.001 2.28 1.75- 2.98
Calcium blocker .003 1.68 1.2- 2.40
Digoxin .096 1.85 0.88- 3.86
Abbreviations: CI, confidence interval; OR, odds ratio.
TA B L E  5  Predictors	of	QTc	≥	500	ms
Risk factor
Univariate analysis Multivariate analysis
P value OR 95% CI P value OR 95% CI
Heart failure .078 1.39 0.96- 1.99
Chronic kidney disease <.001 1.84 1.29- 2.60
Acute renal 
dysfunction
<.001 1.92 1.54- 2.40 <.001 2.40 1.70- 3.40
Acute hepatic 
dysfunction
.002 1.53 1.17- 2.00
Hydroxychloroquine <.001 1.85 1.47- 2.34 .086 1.50 0.94- 2.40
Lopinavir- ritonavir <.001 0.62 0.48- 0.79
Azithromycin 
coadministration
<.001 2.02 1.60- 2.55
Oseltamivir .041 0.55 0.30- 0.98
Remdesivir .059 0.45 0.19- 1.05
Furosemide <.001 2.00 1.50- 2.66
Betablocker <.001 1.60 1.27- 2.02 .023 1.50 1.05- 2.10
Abbreviations: CI, confidence interval; OR, odds ratio.
TA B L E  6  Predictors	of	∆QT	≥	60	ms
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hypokalaemia during treatment remained as independent predic-
tors of TdP (Table 7).
Of	the	2365	patients	in	the	whole	study	cohort,	231	(9.8%)	died	
during the study period. In comparison with those who survived, 
the patients who died were older, more likely to be men, more 
likely to have coronary artery disease, heart failure, CKD, diabe-
tes, hypertension and more likely to receive hydroxychloroquine, 
lopinavir- ritonavir, combination therapy, furosemide, amiodarone, 
beta- blockers and digoxin, and more likely to experience hypokalae-
mia,	acute	renal	or	liver	dysfunction,	QTc	≥	500	ms	and	∆QTc	≥	60	ms	
during treatment. However, age, azithromycin combination therapy, 
greater amiodarone exposure, furosemide therapy and acute renal 
dysfunction remained as independent predictors of mortality in mul-
tivariate analysis (Table 8). Survival analysis of the eight drug reg-
imens showed clear increase in mortality among the patients who 
received hydroxychloroquine or lopinavir- ritonavir with and without 
azithromycin combination therapy (Figure 1).
4  | DISCUSSION
In present cohort of 2365 patients with COVID- 19, primary outcome 
of	critical	QT	prolongation	defined	as	QTc	≥	500	ms	or	∆QTc	≥	60	ms	
was	 observed	 in	 11.2%	 and	 17.6%	 of	 the	 patients,	 respectively.	
There	were	9	people	 (0.38%)	of	 the	secondary	outcome	of	TdP	 in	
entire cohort.
To the best of our knowledge, this is the largest multicentre study 
reporting on QT prolongation and arrhythmic complications of treat-
ment with multiple repurposed drugs in patients with COVID- 19. 
Although there is some information on cardiac safety of chloroquine 
and hydroxychloroquine with and without azithromycin in patients with 
COVID- 19,14- 16 our current knowledge on cardiac safety of other repur-
posed medications for the COVID- 19 treatment is limited. Present co-
hort included a large dataset on cardiac safety of hydroxychloroquine, 
lopinavir- ritonavir and oseltamivir with and without azithromycin. This 
study, for the first time, systematically investigated the QT prolongation 
and arrhythmogenicity in patients with COVID- 19 who were treated 
with atazanavir- ritonavir, favipiravir and remdesivir. We showed that all 
eight COVID- 19 medications were associated with some degree of QTc 
prolongation. Maximal QTc interval prolongation observed in chloro-
quine combination with azithromycin and favipiravir monotherapy was 
associated with minimum QT prolongation. Combination therapy with 
azithromycin led to a significantly greater increase in the QTc interval 
when compared with monotherapy. Hydroxychloroquine use and com-
bination therapy with azithromycin were predictors for having critical 
QT prolongation during treatment. All cases of the TdP occurred in 
combination therapy group. Although critical QT prolongation was as-
sociated with higher risk of TdP, only treatment with lopinavir- ritonavir, 
simultaneous administration of amiodarone or furosemide and hypo-
kalaemia could predict the occurrence of TdP during therapy. Of the 
COVID- 19 medications evaluated in this study, azithromycin combina-
tion therapy also predicted a higher risk of mortality.
Risk factor
Univariate analysis Multivariate analysis
P value OR 95% CI P value OR 95% CI
Non- ischemic heart 
disease
.012 4.66 1.24- 17.40
Coronary artery 
disease
.068 3.38 0.84- 13.6
Heart failure .004 6.00 1.50- 24.4
Chronic kidney 
disease
.003 6.40 1.60- 26.0
Chronic liver disease <.001 19.5 2.30- 165.8
Lopinavir- ritonavir .080 3.05 0.82- 11.40 .006 8.2 1.84- 36.0
Azithromycin 
coadministration
.012 0.58 0.57- 0.60
Furosemide <.001 9.08 2.40- 34.0 .030 4.83 1.16- 20.0
Metolazone <.001 36.6 4.10- 328.4 .028 34.7 1.46- 826
QT prolonging drugs .021 4.47 1.11- 18.0
Amiodarone <.001 31.3 7.54- 130.0 .002 14.5 2.74- 77.0
Hypokalaemia <.001 8.40 2.10- 34.0 .006 8.50 1.84- 39.3
Hypocalcaemia .025 4.03 1.07- 15.0
Acute renal 
dysfunction
.040 3.60 0.97- 13.6
QTc	≥	500	ms .036 3.97 0.99- 16.0
∆QT	≥	60	ms <.001 9.46 2.36- 38.0
Abbreviations: CI, confidence interval; OR, odds ratio.
TA B L E  7   Predictors of torsade de 
pointes
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Effect of chloroquine/hydroxychloroquine with and without 
azithromycin on QTc interval and TdP has been studied in several 
cohorts of COVID- 19 patients.14- 16 In the present study, 1430 pa-
tients who were treated with hydroxychloroquine with or without 
azithromycin	developed	QTc	≥	500	ms	in	14%,	∆QTc	≥	60	ms	in	21%	
and	 TdP	 in	 0.3%	 of	 the	 patients.	 Female	 gender,	 history	 of	 heart	
failure, acute hepatic dysfunction, treatment with hydroxychloro-
quine, azithromycin combination therapy and simultaneous furose-
mide	therapy	were	significant	predictors	of	QTc	≥	500	ms	In	largest	
published study, 415 patients with COVID- 19 from 3 hospitals who 
were treated with hydroxychloroquine/azithromycin were prospec-
tively included.15	Critical	QTc	prolongation	≥500	ms	was	detected	
in	21%	of	patients	and	no	instance	of	TdP	was	reported.	Age,	body	
mass index <30 kg/m2, heart failure, elevated creatinine and peak 
troponin >0.04	mg/ml	were	significant	predictors	of	QTc	≥	500	ms	
Second important study reported the retrospective analysis of 251 
patients with COVID- 19 from 2 centres who were treated with com-
bination of hydroxychloroquine and azithromycin.16 On- treatment 
QTc	≥	500	ms	had	developed	in	23%	of	the	patients,	∆QTc	≥	60	ms	
in	22%	was	seen	in	20%	of	the	patients,	and	one	patient	experienced	
TdP	 (0.4%).	 Baseline	 QTc	 interval	 and	 simultaneous	 amiodarone	
therapy	were	predictors	for	QTc	≥	500	ms	and	baseline	creatinine	
level and simultaneous amiodarone therapy were predictors of si-
multaneous amiodarone therapy.
In addition to chloroquine/hydroxychloroquine with and with-
out azithromycin, we studied the effect of five other antiviral re-
purposed drugs on QT interval prolongation and arrhythmic events. 
Lopinavir- ritonavir and atazanavir- ritonavir, two fixed- dose com-
bination antiretroviral medications, repurposed for COVID- 19 
treatment in the light of some efficacy in the SARS- CoV and the 
Middle- East Respiratory Syndrome Coronavirus (MERS- CoV).19 
Lopinavir/ritonavir	 and	 atazanavir/ritonavir	 were	 used	 29%	 and	
0.7%	of	our	patients,	respectively.	Azithromycin	was	added	to	30%	
of	 the	patients	 in	 lopinavir/ritonavir	 group	and	25%	 in	atazanavir/
ritonavir group. Treatment with lopinavir- ritonavir increased the risk 
of TdP by more than 8 times; five cases of TdP occurred in patients 
who are receiving lopinavir- ritonavir and azithromycin combination, 
however, there was no report of TdP in atazanavir- ritonavir group. 
Latter finding may be related to small number (n = 19) of the patients 
who were treated with atazanavir- ritonavir.
Oseltamivir, an antiviral to treat influenza, was used in the early 
days of the COVID- 19 pandemic because there was some evidence 
that the active site of the spike protein of SARS- COV2 virus is similar 
to that of influenza virus neuraminidase, suggesting that neuramin-
idase inhibitors (eg oseltamivir) may be useful to treat COVID- 19. 
In	 the	 present	 study,	 it	was	 used	 in	 5%	 of	 the	 patients	mainly	 as	
combination therapy with azithromycin. Oseltamivir use signifi-
cantly increased baseline QT and led to critical QT prolongation as 
Risk factor
Univariate analysis Multivariate analysis
P value OR 95% CI P value OR 95% CI
Age <.001 10 9.0- 13.0 <.001 1.03 1.02- 1.04
Male gender .014 1.40 1.07- 1.88
Coronary artery disease <.001 2.00 1.50- 2.90
Heart failure <.001 2.40 1.60- 3.56
Chronic kidney disease <.001 2.90 1.98- 4.30
Diabetes mellitus .012 1.40 1.08- 1.89
Hypertension .002 1.55 1.18- 2.04
Hydroxychloroquine .003 1.57 1.17- 2.10
Lopinavir/ritonavir .008 0.65 0.47- 0.89
Azithromycin 
coadministration
<.001 2.33 1.70- 3.20 <.001 2.23 1.60- 3.10
Furosemide <.001 5.09 3.75- 6.90 <.001 2.60 1.84- 3.65
Amiodarone <.001 4.65 2.37- 9.15 .033 2.37 1.07- 5.27
Beta- blocker <.001 2.46 1.86- 3.25
Digoxin <.001 4.88 2.64- 9.05
Hypokalaemia .002 1.60 1.18- 2.20
On- treatment 
QTc	≥	500	ms
<.001 2.84 2.03- 3.97
∆QT	≥	60	ms <.001 2.40 1.78- 3.24
Acute renal dysfunction <.001 5.70 4.30- 7.58 <.001 3.70 2.73- 5.02
Acute hepatic 
dysfunction
<.001 1.77 1.27- 2.45
Abbreviations: CI, confidence interval; OR, odds ratio.
TA B L E  8   Predictors of mortality
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QTc	≥	500	ms	 in	6.6%	and	∆QTc	≥	60	ms	 in	11%	of	 the	patients.	
However, there were no instances of oseltamivir- related TdP in en-
tire cohort. In a small study, Celik et al20 critical QTc prolongation 
(QTc	≥	500	ms	or	∆QTc	≥	60	ms)	was	detected	in	12%	of	the	popula-
tion. The use of oseltamivir in combination with hydroxychloroquine 
and azithromycin was found to cause critical QTc prolongation more 
F I G U R E  1   Survival function estimated by the Kaplan- Meier analysis among the eight different drug regimens used to treat COVID- 19. 
Log- rank P- value was significant among the patients who received hydroxychloroquine or lopinavir- ritonavir with and without azithromycin 
combination therapy
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than five times. Both studies indicate that we should be more careful 
when prescribing the combination of oseltamivir with COVI- 19 med-
ications during influenza season.
Favipiravir is an oral drug that was approved for influenza and 
Ebola- virus infection. In our study, favipiravir monotherapy was 
safer than other COVID- 19 mediations in terms of QTc prolongation. 
Of the 33 patients on favipiravir therapy, there were one patient 
(3%)	of	QTc	≥	500	ms	and	3	patients	(9%)	of	∆QTc	≥	60	ms,	however,	
no TdP was observed. In a case report, QTc prolongation was ob-
served on the 9th day of treatment in a patient who was using favip-
iravir for Ebola virus infection.21 However, small study by Cap et al in 
COVID- 19 patients showed no significant increase in QTc interval.22 
Together, available data indicate that favipiravir is better tolerated in 
terms of cardiac arrhythmia in COVID- 19 patients.
Remdesivir originally tested in patients with Ebola, now the FDA 
approved an Emergency Use Authorisation to allow treatment of 
COVID- 19 patients hospitalised with severe disease.11 Currently, 
there is little data on QT prolonging effect of this drug. In our se-
ries of 67 patients on remdesivir, there was significant increase in 
QTc	interval.	In	addition,	we	observed	6	cases	(9%)	of	QTc	≥	500	ms	
and	6	cases	(9%)	of	∆QTc	≥	60	ms,	however,	no	instance	of	TdP	was	
reported. There is only one case report of critical QT prolongation 
(555 ms) in COVID- 19 patient following third dose of a 5- day treat-
ment with remdesivir.23 It is important to note that this patient was 
on azithromycin while receiving remdesivir which is well known to 
prolong the QT interval. It is possible that it contributed to the pro-
longation of the QT interval in this patient. However, in our study, all 
patients received remdesivir monotherapy. It appears that remde-
sivir monotherapy, among the COVID- 19 medications studied, has a 
low- risk profile in terms of QT prolongation and TdP induction.
Repurposed drugs used in COVID- 19 treatment cause QT pro-
longation by blocking the voltage- gated ion channel that mediates 
the rapid component of the delayed rectifier potassium current, 
IKr, resulting in lengthening of the ventricular action potential.24 
A timely early Afterdepolarisation, in the presence of a prolonged 
QT interval, may result in TdP. This risk increases in the presence 
of concomitant use of QT prolonging agents, loop diuretic, female 
gender, elderly people, structural heart disease, heart failure, myo-
cardial infarction, electrolyte disturbances, bradycardia, renal dis-
ease and hepatic disease.25 In addition, concomitant cardiac injury 
from SARS- CoV- 2 infection may increase the risk of adverse events 
from generally safe drugs.26 We similarly showed that female gen-
der, history of heart failure, treatment with hydroxychloroquine, 
azithromycin combination therapy, simultaneous furosemide or 
beta- blocker therapy, and acute renal or hepatic dysfunction were 
independent increased risk of the critical QT prolongation, however, 
the risk of TdP increased with lopinavir- ritonavir use, amiodarone or 
loop diuretic coadministration and hypokalaemia during treatment. 
Drug- induced bradycardia is the common mechanism for the QT 
prolongation following amiodarone, beta- blocker and digoxin use,25 
however, amiodarone has also a known risk of prolonging QTc sec-
ondary to action potential prolongation.27 We also observed that the 
risk of mortality increased independently by azithromycin combina-
tion therapy, simultaneous amiodarone or loop diuretic therapy, and 
acute renal dysfunction.
Importance of ECG monitoring has been studied in a recent mul-
ticentre study in 6476 hospitalised patients with COVID- 19 who 
were treated with hydroxychloroquine with or without azithromy-
cin.28 Using a simplified approach to monitoring for QT prolonga-
tion	and	arrhythmia,	TdP	was	observed	in	1	(0.015%)	patient	and	67	
(1.03%)	patients	had	hydroxychloroquine	with	and	without	azithro-
mycin held or discontinued as a result of excessive QT prolongation.
Practical recommendations for healthcare providers: (1) 
Considering the limited efficacy and important safety concerns, 
we think that chloroquine/hydroxychloroquine, fixed- dose com-
bination antiretroviral medications with and without azithromycin 
should be avoided in COVID- 19 treatment. (2) Although mono-
therapy with oseltamivir, favipiravir and remdesivir are better tol-
erated in terms of the critical QT prolongation and TdP, treatment 
with these drugs still needs close ECG monitoring for QT prolon-
gation. (3) Optimisation of renal/hepatic functions and electrolyte 
status is highly recommended. (4) Simultaneous use of antiarrhyth-
mic drugs such as amiodarone, beta- blockers, etc is discouraged.
4.1 | Limitations
Results of the present study should be interpreted in the light of 
certain limitations: first, patients without a baseline or postmedica-
tion ECGs were excluded from the analysis, which can represent a 
bias. We tried to minimise this bias by the consecutive inclusion of 
patients meeting study criteria. Second, the present cohort was con-
sisted of hospitalised patients, and the results may not apply to out-
patient setting or prophylactic treatments. Third, although a specific 
dosing schedule was recommended by national COVID- 19 guide-
lines for all physicians, the decisions when and how to prescribe 
these drugs were deferred to the prescribing physicians.
5  | CONCLUSIONS
Hospitalised COVID- 19 patients treated with chloroquine, hydroxy-
chloroquine, lopinavir/ritonavir, atazanavir/ritonavir, oseltamivir, 
favipiravir and remdesivir alone or in combination with azithromy-
cin had a significant increase in QTc during drug therapy. Several 
risk factors identified patients at risk of critical QTc prolongation. 
Despite this finding, life- threatening arrhythmia of TdP occurred 
rarely. Among the repurposed drugs studied, hydroxychloroquine or 
lopinavir- ritonavir alone or in combination with azithromycin clearly 
demonstrated to increase the risk of critical QT prolongation or in-
duction of TdP.
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